Table 1.

Patients’ characteristics

Variables	Secukinumab	Ixekizumab
Demographics
Number of patients	140	45
Male/female	78/62	34/11
Mean age (years)	49 (19-85)	48 (19-73)
Diagnosis (%)
Pso	74 (52.86)	33 (73.33)
PsA	66 (47.14)	12 (26.6)
Candidiasis risk factors (%)
Obesity	47 (33.81)	2 (5)
DM2	13 (9.35)	3 (7)
Older 65 years (%)	19 (13.67)	5 (11)
Previous biologic therapy (%)	69 (49.29)	33 (73.33)
Mean treatment duration (weeks)	74.64 (4-194.71)	42.86 (7.86-20.86)

Pso=Psoriasis, PsA=Psoriatic arthritis, DM2=Type 2 diabetes mellitus